{
  "id": 11172904,
  "title": "Monte Rosa reports positive phase 1 data for MRT-8102",
  "url": "https://urgent.news/2026/10/01/monte-rosa-reports-positive-phase-1-data-for-mrt-8102",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-01T11:04:34.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/monte-rosa-reports-positive-phase-1-data-for-mrt8102-93CH-4927075"
  },
  "original_language": "en",
  "account": null,
  "summary": "Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) has announced positive phase 1 data for its investigational drug MRT-8102, a molecular glue degrader targeting NEK7 for the treatment of inflammatory conditions. The GFORCE-1 Phase 1 study enrolled 108 obese subjects with elevated cardiovascular disease risk and administered MRT-8102 at once-daily doses of 5 mg, 20 mg, or 40 mg, or placebo for four weeks, followed by safety follow-up. The results showed median NEK7 degradation of approximately 80% to 90% across all three dose levels, as well as reductions in multiple biomarkers associated with atherosclerotic cardiovascular disease. Notable reductions included calprotectin (56%), S100A12 (46%), and SAA (51%) by median values, as well as HMGB1 (40%) and IL-1β (37%) in subjects with top quartile levels. The drug also reduced IL-6 and hsCRP by 54% and 85%, respectively, with no increases in LDL-C or triglyceride levels. MRT-8102 was well tolerated, with no serious adverse events reported. Monte Rosa plans to initiate further studies in coronary artery disease, gout, and hidradenitis suppurativa based on these promising results.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}